IDEXX Laboratories, Inc. Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
13.3%projected annual EPS growth
Analyst Coverage
13analysts covering
FY Revenue (est.)
$4.7Bnext fiscal year
FY EPS (est.)
$14.83next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Next Earnings Release | 2 Nov 2026 |
Monitoring Framework
Key Performance Indicators
CAG Diagnostics recurring-revenue organic growth Quarterly10.3%Target: FY2026 guidance: 9.5%-10.7%
Operating margin Quarterly35.0%Target: FY2026 guidance: 32.3%-32.5%
IDEXX inVue Dx installed base and placements; Q2 2026 installed base exceeded 9,000 instruments with more than 1,600 quarterly placements Quarterly
Watch Items
- CAG Diagnostics recurring-revenue organic growth relative to the lower bound of management's FY2026 guidance
- Full-year operating-margin delivery relative to the lower bound of management's FY2026 guidance
Research as of 29 Aug 2026